Prediction of breakthrough hepatitis due to lamivudine-resistant hepatitis B virus by a sensitive semiquantitative assay using peptide nucleic acids

Intervirology

Volumn 49, Issue 5, 2006, Pages 274-280

  Mori, Kojiro ^a   Minami, Masahito ^a   Kirishima, Toshihiko ^a   Kunimoto, Koji ^a   Okita, Mika ^a   Nakayama, Mika ^a   Makiyama, Akiko ^a   Yamaoka, Junko ^a   Nakajima, Tomoki ^a   Yasui, Kohichiroh ^a   Itoh, Yoshito ^a   Okanoue, Takeshi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Breakthrough hepatitis; Hepatitis B virus; Lamivudine resistance; PCR clamping; Peptide nucleic acids

Indexed keywords

ALANINE AMINOTRANSFERASE; LAMIVUDINE; PEPTIDE; PEPTIDE NUCLEIC ACID; TYROSYLMETHIONYLASPARTYLASPARTIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; EARLY DIAGNOSIS; FEMALE; HEPATITIS; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY ANALYSIS; VIRUS INFECTION; VIRUS MUTANT; VIRUS REPLICATION;

ADULT; AGED; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PEPTIDE NUCLEIC ACIDS; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS;

HEPATITIS B VIRUS;

EID: 33747259603     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093457     Document Type: Article

References (27)

1. Conjeevaram HS, Lok ASF: Management of chronic hepatitis B. J Hepatol 2003;38:S90-S103.
2. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC: Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′- thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-8499.
3. Chang CN, Skalski V, Zhou JH, Cheng YC: Biochemical pharmacology of (+)-and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992;267:22414-22420.
4. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
5. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF: A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
6. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER: Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-117.
7. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ: Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-713.
8. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL: Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-717.
9. Leung N: Viral breakthrough during lamivudine therapy for chronic hepatitis B. Intervirology 2003;46:344-349.
10. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-1677.
11. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM: Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-572.
12. Perrillo RP: Management of the patient with hepatitis B virus-related cirrhosis. J Hepatol 2003;39:S177-S180.
13. Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, Toyama T, Minami M: Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 2002;37:259-265.
14. Okanoue T, Mori K, Kirishima T, Kunimoto K, Yasui K, Itoh Y, Minami M: Lamivudine therapy for Japanese patients with cirrhosis B. Intervirology 2003;46:394-399.
15. Lau DTY, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH: Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-834.
16. Paik YH, Chung HY, Ryu WS, Lee KS, Lee JS, Kim JH, Lee CK, Chon CY, Moon YM, Han KH: Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea. J Hepatol 2001;35: 92-98.
17. Kobayashi S, Ide T, Sata M: Detection of YMDD motif mutants in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001;34:584-586.
18. Gilliland G, Perrin S, Blanchard K, Bunn HF: Analysis of cytokine mRNA and DNA: Detection and quantitation by competitive polymerase chain reaction. Proc Natl Acad Sci USA 1990;87:2725-2729.
19. Siebert PD, Larrick JW: Competitive PCR. Nature 1992;359:557-558.
20. Punia P, Cane P, Teo CG, Saunders N: Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. J Hepatol 2004;40:986-992.
21. Bock C-T, Tillman HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, Trautwein C: Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002;122:264-273.
22. Marcellin P, Chang T-T, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL, Adefovir Dipivoxil 437 Study Group: Adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hepatitis B. N Eng J Med 2003;348:808-816.
23. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL, Adefovir Dipivoxil 438 Study Group: Adefovir dipivoxil for the treatment of hepatitis Be antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
24. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, Dehertogh D: Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-1838.
25. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M: The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001;107:449-455.
26. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A: Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134.
27. Humphries JC, Dixon JS: Antivirals for the treatment of chronic hepatitis B: Current and future options. Intervirology 2003;46:413-420.